295 related articles for article (PubMed ID: 22456297)
1. Relationship between serum allantoin and urate in healthy subjects and effects of benzbromarone in gout patients.
Kurajoh M; Koyama H; Shoji T; Sumida C; Yamamoto A; Tsutsumi Z; Moriwaki Y; Yamamoto T; Koga M
Int J Clin Pharmacol Ther; 2012 Apr; 50(4):265-71. PubMed ID: 22456297
[TBL] [Abstract][Full Text] [Related]
2. Influence of urate-lowering therapies on renal handling of uric acid.
Ma L; Wei L; Chen H; Zhang Z; Yu Q; Ji Z; Jiang L
Clin Rheumatol; 2016 Jan; 35(1):133-41. PubMed ID: 25373449
[TBL] [Abstract][Full Text] [Related]
3. Uricosuric medications for chronic gout.
Kydd AS; Seth R; Buchbinder R; Edwards CJ; Bombardier C
Cochrane Database Syst Rev; 2014 Nov; (11):CD010457. PubMed ID: 25392987
[TBL] [Abstract][Full Text] [Related]
4. Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study.
Hosoya T; Sano T; Sasaki T; Fushimi M; Ohashi T
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):62-70. PubMed ID: 31980978
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.
Perez-Ruiz F; Alonso-Ruiz A; Calabozo M; Herrero-Beites A; García-Erauskin G; Ruiz-Lucea E
Ann Rheum Dis; 1998 Sep; 57(9):545-9. PubMed ID: 9849314
[TBL] [Abstract][Full Text] [Related]
6. Randomized, Open-Label, Cross-Over Comparison of the Effects of Benzbromarone and Febuxostat on Endothelial Function in Patients with Hyperuricemia.
Nakata T; Ikeda S; Koga S; Yonekura T; Tsuneto A; Doi Y; Fukae S; Minami T; Kawano H; Maemura K
Int Heart J; 2020 Sep; 61(5):984-992. PubMed ID: 32921665
[TBL] [Abstract][Full Text] [Related]
7. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients.
Reinders MK; van Roon EN; Houtman PM; Brouwers JR; Jansen TL
Clin Rheumatol; 2007 Sep; 26(9):1459-65. PubMed ID: 17308859
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Benzbromarone and Febuxostat in Hyperuricemia Patients with Chronic Kidney Disease: A Prospective Pilot Study.
Yu H; Liu X; Song Y; Cheng J; Bao H; Qin L; Zhou X; Wang L; Peng A
Clin Exp Nephrol; 2018 Dec; 22(6):1324-1330. PubMed ID: 29761242
[TBL] [Abstract][Full Text] [Related]
9. Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia.
Kuriyama S
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):1-5. PubMed ID: 31754883
[TBL] [Abstract][Full Text] [Related]
10. Major unanswered questions in the clinical gout field.
Stamp LK
Curr Opin Rheumatol; 2017 Mar; 29(2):171-177. PubMed ID: 27926541
[TBL] [Abstract][Full Text] [Related]
11. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study.
Ogino K; Kato M; Furuse Y; Kinugasa Y; Ishida K; Osaki S; Kinugawa T; Igawa O; Hisatome I; Shigemasa C; Anker SD; Doehner W
Circ Heart Fail; 2010 Jan; 3(1):73-81. PubMed ID: 19933411
[TBL] [Abstract][Full Text] [Related]
12. Myeloperoxidase and oxidation of uric acid in gout: implications for the clinical consequences of hyperuricaemia.
Stamp LK; Turner R; Khalilova IS; Zhang M; Drake J; Forbes LV; Kettle AJ
Rheumatology (Oxford); 2014 Nov; 53(11):1958-65. PubMed ID: 24899662
[TBL] [Abstract][Full Text] [Related]
13. [The effect of benzbromaron in gout patients with limited kidney function].
Kuzmits R; Bresnik W; Müller MM
Fortschr Med; 1979 Nov; 97(44):2057-61. PubMed ID: 511087
[TBL] [Abstract][Full Text] [Related]
14. Does a relationship exist between the urate pool in the body and lipid peroxidation during exercise?
Mikami T; Yoshino Y; Ito A
Free Radic Res; 2000 Jan; 32(1):31-9. PubMed ID: 10625215
[TBL] [Abstract][Full Text] [Related]
15. Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study.
Shiramoto M; Liu S; Shen Z; Yan X; Yamamoto A; Gillen M; Ito Y; Hall J
Rheumatology (Oxford); 2018 Sep; 57(9):1602-1610. PubMed ID: 29868853
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of benzbromarone versus febuxostat in gouty patients: a retrospective study.
Liu D; Zhou B; Li Z; Zhang Z; Dai X; Ji Z; Chen H; Sun Y; Jiang L
Clin Rheumatol; 2022 Jul; 41(7):2121-2128. PubMed ID: 35229198
[TBL] [Abstract][Full Text] [Related]
17. Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with gout.
Perez-Ruiz F; Hernandez-Baldizon S; Herrero-Beites AM; Gonzalez-Gay MA
Arthritis Care Res (Hoboken); 2010 Sep; 62(9):1299-305. PubMed ID: 20506124
[TBL] [Abstract][Full Text] [Related]
18. [Usefulness of combination treatment using allopurinol and benzbromarone for gout and hyperuricemia accompanying renal dysfunction: kinetic analysis of oxypurinol].
Ohno I; Okabe H; Yamaguchi Y; Saikawa H; Uetake D; Hikita M; Gomi H; Ichida K; Hosoya T
Nihon Jinzo Gakkai Shi; 2008; 50(4):506-12. PubMed ID: 18546882
[TBL] [Abstract][Full Text] [Related]
19. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.
Reinders MK; Haagsma C; Jansen TL; van Roon EN; Delsing J; van de Laar MA; Brouwers JR
Ann Rheum Dis; 2009 Jun; 68(6):892-7. PubMed ID: 18633127
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of benzbromarone in hyperuricemic patients associated with chronic kidney disease.
Fujimori S; Ooyama K; Ooyama H; Moromizato H
Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1035-8. PubMed ID: 22132953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
